Articles
Proteomics feature: The new biodiversity
What began as a trickle of new genes in the late 1970s has become a flood, as genomics projects deliver new genetic maps, huge catalogues of genes, and a ticker-tape blizzard of DNA sequences almost every other week. [ + ]
Business development feature: Do you go with the pros?
Good ideas and good science are not the only things a biotechnology company needs to get itself off the ground. In order to raise the amount of capital needed to take a company from being a mere glint in the eye of a scientist to a successful, publicly listed biotechnology company requires a lot of behind the scenes planning and strategy, business acumen, and networking. [ + ]
Interview: Brain research resonates for BRI scientist
Tucked away in the corner of the Austin and Repatriation Medical Centre campus in Melbourne suburb of Heidelberg is the Brain Research Institute (BRI), devoted to research into epilepsy and other neural disorders, as well as the function of the healthy brain. [ + ]
Bioclusters feature: Get it together
Bioclusters are complex animals whose care and feeding now commands respectful attention in the upper echelons of Australia's biotechnology community. [ + ]
Mouse models feature: How to make a mutant mouse
There are two basic types of rodent model for investigating inherited genetic disorders or health problems in humans -- the 'knockout' and the 'knock-in' mouse. [ + ]
Mouse models feature: The quest for an epileptic mouse
As you read these words, charged sodium, potassium and calcium atoms are streaming through tiny pores in the membranes of billions of nerve cells in your brain, generating the seething electrical activity that underlies conscious thought. [ + ]
Mouse models feature: It's a knockout
Making mutant mice was once a challenge, but in the Speedy Gonzales business of biotech and medical research, it's now routine, and a time-consuming distraction from the real game of investigating gene function. [ + ]
Asia gets serious about bio-IT
Great strides made in the areas of genomics, proteomics and other key features across the developing biotech landscape have dramatically altered the playing field for bioinformatics groups Asia is now expected to realize a massive surge in demand for IT systems as the region races to catch up with the rest of the world. [ + ]
Thermometric titrimetry puts heat back into the titration game
Thermometric titrimetry is versatile, robust, fast and reliable, ideally suited to the demands of modern process and quality control laboratories
[ + ]Finding new meaning in microscope images
A team of computer scientists working with cell biologists at Lawrence Berkeley National Laboratory has created BioSig, a web-based bioinformatic system that links collections of microscope images to a wide variety of quantitative experimental data
[ + ]Devices of industry
Outside the industry, the words 'Australian biotechnology' immediately conjure up three names in particular -- CSL, Cochlear and ResMed. The irony is that none of these companies is strictly a biotechnology company. [ + ]
Biotech breathes life into ethanol R&D
Oil prices are again pushing $US30 a barrel, glaciers are melting, and cuckoos are announcing spring in Europe's woodlands some 16 days earlier than they did half a century ago. And not for the first time since the OPEC-engineered oil supply crisis of the mid-1970s, an Australian government is talking up the need to develop a local fuel ethanol industry. [ + ]
Parliamentary debate continues on stem cells
Behind the headlines, hype and huff-and-puff politics surrounding the therapeutic use of stem cells, there is fierce debate even among the experts over which research route holds the greater promise: adult, or embryonic? [ + ]
Smelling a rat
Trapped in the political crossfire of the stem cell debate, biotech industry icon Prof Alan Trounson has taken some heavy hits. [ + ]
Thinking big? Think US, advises new Biota chief
The single most important thing an Australian biotechnology company can do to increase its chances of success, according to new Biota Holdings CEO Peter Molloy, is to be on the ground in the US. [ + ]